Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2014

01-10-2014 | Research Article

Effectiveness of pharmacist intervention in patients with chronic kidney disease

Authors: Aurelio Cabello-Muriel, Juan José Gascón–Cánovas, Elena Urbieta-Sanz, Carles Iniesta-Navalón

Published in: International Journal of Clinical Pharmacy | Issue 5/2014

Login to get access

Abstract

Background Collaboration between pharmacists and physicians in the care of patients with chronic kidney disease (CKD) may improve the quality of drug dosage regimens that require adjustment according to the renal function. Objective To demonstrate that the intervention of a pharmacist in a monitoring program for patients with CKD improves the outcome of renal function in these patients. Setting A 330-bed regional referral hospital in the city of Murcia (Spain). Method All patients with CKD and taking nephrotoxic medication admitted to the internal medicine service were included in the study. Depending on the department of the hospital to which the patients were admitted, they were assigned to an intervention or control group. In the control group, the renal function at the time of admission and discharge was measured. In the intervention group, in addition to measuring kidney function at the time of admission and at discharge, the patients were followed daily and recommendation for dose adjustment were made when nephrotoxic drugs were not properly dosed. Main outcome measure Glomerular filtration rate on admission and at discharge. Results A total of 249 patients were included in the study, 124 in the control group and 125 in the intervention group. Significant differences were noted when comparing creatinine clearance (CrCl) between discharge and admission in both the control and intervention groups (5.1 ± 0.9 vs. 6.4 ± 1.0 p < 0.01). In a comparison of the observed improvement in the two groups, we found significant differences in adjusted relative CrCl according to sex, age and stage (19.9 [1.2–38.5] p < 0.05). When the disease was analyzed by stage, we observed significant differences that favored the intervention group in regards CrCl (3.1 ± 2.1 vs. 7.9 ± 3.8 p < 0.05) and relative CrCl (16.1 ± 10.3 vs. 36.6 ± 16.7) in stages 4–5. The rate of acceptance of the pharmacists’ recommendations was 74 %. Conclusion The implementation of a monitoring program for CKD patients was effective in the group in which monitoring was conducted, especially in patients with more advanced stage of CKD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adults US population: Third Natinonal Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.PubMedCrossRef Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adults US population: Third Natinonal Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.PubMedCrossRef
2.
go back to reference Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.PubMedCrossRef Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.PubMedCrossRef
3.
go back to reference Otero A, de Francisco ALM, Gayoso P, García F, et al. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrología. 2010;30:78–86.PubMed Otero A, de Francisco ALM, Gayoso P, García F, et al. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrología. 2010;30:78–86.PubMed
4.
go back to reference Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, Seger DL, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839–44.PubMedCrossRef Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, Seger DL, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839–44.PubMedCrossRef
5.
go back to reference Alvarez L, Climent E, Bosacoma N, Roca S, Perdiguero M, Ordovás JP, et al. Evaluación de un programa de intervención farmacéutica en pacientes con medicamentos de riesgo renal [Evaluation of a pharmaceutical intervention program in patients with renal risk drugs]. Farm Hosp. 2009;33:147–54 Spanish.CrossRef Alvarez L, Climent E, Bosacoma N, Roca S, Perdiguero M, Ordovás JP, et al. Evaluación de un programa de intervención farmacéutica en pacientes con medicamentos de riesgo renal [Evaluation of a pharmaceutical intervention program in patients with renal risk drugs]. Farm Hosp. 2009;33:147–54 Spanish.CrossRef
6.
go back to reference Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136:604–15.PubMedCrossRef Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136:604–15.PubMedCrossRef
7.
go back to reference Blix HS, Viktil KK, Moger TA, Reikvam A. Use of renal risk drugs in hospitalized patients with impaired renal function-an understaimated problem? Nephrol Dial Transplant. 2006;21:3164–71.PubMedCrossRef Blix HS, Viktil KK, Moger TA, Reikvam A. Use of renal risk drugs in hospitalized patients with impaired renal function-an understaimated problem? Nephrol Dial Transplant. 2006;21:3164–71.PubMedCrossRef
8.
go back to reference Fabregas X, Agustí C, Gurrera T, Felip A. Evaluación de la intervención farmacéutica en un programa de reajuste de dosis en pacientes con función renal alterada [Evaluation of pharmaceutical intervention in a dose adjustment program in patients with impaired renal function]. Farm Hosp. 2003;27(Supl 1):28. Spanish. Fabregas X, Agustí C, Gurrera T, Felip A. Evaluación de la intervención farmacéutica en un programa de reajuste de dosis en pacientes con función renal alterada [Evaluation of pharmaceutical intervention in a dose adjustment program in patients with impaired renal function]. Farm Hosp. 2003;27(Supl 1):28. Spanish.
9.
go back to reference Falconnier AD, Haeffeli WE, Schonenberger RA, Surber C, Martin-Facklam M. Drug dosage in patients with renal failure optimized by inmediate concurrent feedback. J Gen Intern Med. 2001;16:369–75.PubMedCrossRefPubMedCentral Falconnier AD, Haeffeli WE, Schonenberger RA, Surber C, Martin-Facklam M. Drug dosage in patients with renal failure optimized by inmediate concurrent feedback. J Gen Intern Med. 2001;16:369–75.PubMedCrossRefPubMedCentral
10.
go back to reference Lavilla FJ, Ferrer A. Fracaso renal agudo: clasificación, etiopatogenia y factores pronósticos [Acute renal failure: classification, pathogenesis and prognostic factors]. Medicine. 2011;10:5348–55 Spanish. Lavilla FJ, Ferrer A. Fracaso renal agudo: clasificación, etiopatogenia y factores pronósticos [Acute renal failure: classification, pathogenesis and prognostic factors]. Medicine. 2011;10:5348–55 Spanish.
11.
go back to reference Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother. 2004;38:853–8.PubMedCrossRef Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother. 2004;38:853–8.PubMedCrossRef
12.
go back to reference Sweileh WM, Janem SA, Sawalha AF, Abu-Taha AS, Zyoud SH, Sabri IA, et al. Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine. Pharmacoepidemiol Drug Saf. 2007;16:908–12.PubMedCrossRef Sweileh WM, Janem SA, Sawalha AF, Abu-Taha AS, Zyoud SH, Sabri IA, et al. Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine. Pharmacoepidemiol Drug Saf. 2007;16:908–12.PubMedCrossRef
13.
go back to reference Salomon L, Deray G, Jaundon MC, Chebaiser C, Bossi P, Launay-Vacher V, et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care. 2003;15:331–5.PubMedCrossRef Salomon L, Deray G, Jaundon MC, Chebaiser C, Bossi P, Launay-Vacher V, et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care. 2003;15:331–5.PubMedCrossRef
14.
go back to reference Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacist´s interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2011;0:1–17. Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacist´s interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2011;0:1–17.
15.
go back to reference Pai AB, Boyd A, Depczynski J, et al. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy. 2009;29:1433–40.PubMedCrossRef Pai AB, Boyd A, Depczynski J, et al. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy. 2009;29:1433–40.PubMedCrossRef
16.
go back to reference Leung WY, So WY, Tong PC, et al. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005;118:1414.PubMedCrossRef Leung WY, So WY, Tong PC, et al. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005;118:1414.PubMedCrossRef
17.
go back to reference Bucaloiu ID, Akers G, Bermudez MC, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface. 2007;20:26–30.PubMed Bucaloiu ID, Akers G, Bermudez MC, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface. 2007;20:26–30.PubMed
18.
go back to reference Yokum D, Glass G, Cheung CF, et al. Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients. J Ren Nutr. 2008;18:521–9.PubMedCrossRef Yokum D, Glass G, Cheung CF, et al. Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients. J Ren Nutr. 2008;18:521–9.PubMedCrossRef
19.
go back to reference Leal S, Soto M. Chronic kidney disease risk reduction in a Hispanic population through pharmacist-based disease-state management. Adv Chronic Kidney Dis. 2008;15:162–7.PubMedCrossRef Leal S, Soto M. Chronic kidney disease risk reduction in a Hispanic population through pharmacist-based disease-state management. Adv Chronic Kidney Dis. 2008;15:162–7.PubMedCrossRef
20.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
21.
go back to reference Grupo de trabajo de Farmacia y Nefrología. Guía de dosificación de fármacos en insuficiencia renal. HGU Reina Sofía Murcia [Guide to drug dosage in renal failure. HGU Reina Sofia Murcia].2012.Unidad Técnica de Comunicación. Spanish. Grupo de trabajo de Farmacia y Nefrología. Guía de dosificación de fármacos en insuficiencia renal. HGU Reina Sofía Murcia [Guide to drug dosage in renal failure. HGU Reina Sofia Murcia].2012.Unidad Técnica de Comunicación. Spanish.
22.
go back to reference Mensa J, Gatell JM, Garcia-Sanchez JE, Letang E, Lopez-Suñe E, Marco F. Guía de terapéutica antimicrobiana [Guide antimicrobial therapy] 2011. Ed Antares. 2011.Spanish. Mensa J, Gatell JM, Garcia-Sanchez JE, Letang E, Lopez-Suñe E, Marco F. Guía de terapéutica antimicrobiana [Guide antimicrobial therapy] 2011. Ed Antares. 2011.Spanish.
24.
go back to reference David N, Robert C, George M, Henry F, Michael S, The Sanford guide to Antimicrobial Therapy 2011. Forty-first edition. 2011. David N, Robert C, George M, Henry F, Michael S, The Sanford guide to Antimicrobial Therapy 2011. Forty-first edition. 2011.
25.
go back to reference Machin D, Campbell M, Fayers P, Pinol A. Sample size tables for clinical studies. 2nd ed. Blackwell Science; 1997. Machin D, Campbell M, Fayers P, Pinol A. Sample size tables for clinical studies. 2nd ed. Blackwell Science; 1997.
26.
go back to reference Devesa C, Matoses C, Peral L, Sanz G, Murcia AC, Navarro A. Atención farmacéutica en pacientes ingresados con insuficiencia renal [Pharmaceutical care in patients hospitalized with kidney failure]. Farm Hosp. 2012;36:483–91 Spanish. Devesa C, Matoses C, Peral L, Sanz G, Murcia AC, Navarro A. Atención farmacéutica en pacientes ingresados con insuficiencia renal [Pharmaceutical care in patients hospitalized with kidney failure]. Farm Hosp. 2012;36:483–91 Spanish.
27.
go back to reference Montañés-Paul B, Sáez-Lleó C, Martínez-Romero G. Ajuste de dosificación de medicamentos en pacientes ancianos institucionalizados con insuficiencia renal [Adjust dosage of drugs in institutionalized elderly patients with renal insufficiency]. Farm Hosp. 2009;33:43–7 Spanish.CrossRef Montañés-Paul B, Sáez-Lleó C, Martínez-Romero G. Ajuste de dosificación de medicamentos en pacientes ancianos institucionalizados con insuficiencia renal [Adjust dosage of drugs in institutionalized elderly patients with renal insufficiency]. Farm Hosp. 2009;33:43–7 Spanish.CrossRef
28.
go back to reference Nyman H, Dowling T, Hudson J, Peter W, Joy M, Nolin T, et al. Comparative evaluation of the Cockcroft-Gault equation and the modification of diet in renal disease (MDRD) study equation for drug dosing. Pharmacotherapy. 2011;31:1130–44.PubMedCrossRef Nyman H, Dowling T, Hudson J, Peter W, Joy M, Nolin T, et al. Comparative evaluation of the Cockcroft-Gault equation and the modification of diet in renal disease (MDRD) study equation for drug dosing. Pharmacotherapy. 2011;31:1130–44.PubMedCrossRef
29.
go back to reference Stevens L, Nolin T, Richardson M, Feldman H, Lewis J, Rodby R, et al. Comparasion of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney. 2009;54:33–42.CrossRef Stevens L, Nolin T, Richardson M, Feldman H, Lewis J, Rodby R, et al. Comparasion of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney. 2009;54:33–42.CrossRef
Metadata
Title
Effectiveness of pharmacist intervention in patients with chronic kidney disease
Authors
Aurelio Cabello-Muriel
Juan José Gascón–Cánovas
Elena Urbieta-Sanz
Carles Iniesta-Navalón
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2014
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-0001-3

Other articles of this Issue 5/2014

International Journal of Clinical Pharmacy 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.